Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus (I-Seizure)

ID
Name
MIR-2023-01
Description
Isoflurane might be used as anticonvulsive therapy in refractory status epilepticus. The aim of the study is to assess the efficiency of Isoflurane in this indication.
Trial arms
Trial start
2024-03-01
Estimated PCD
2024-09-01
Trial end
2024-12-01
Status
Not yet recruiting
Treatment
Isoflurane
no other intervention
Arms:
Main cohort
Size
120
Primary endpoint
rate of crisis control
3 months
Eligibility criteria
Inclusion Criteria: * Age \> 18 years, hospitalized in ICU between 2016-01-01 and 2023-01-01, suffering refractory status epilepticus treated by inhaled Isoflurane as third anticonvulsive therapy Exclusion Criteria: * post-anoxic refractory status epilepticus after cardiac arrest, withdrawal of consent for medical data use
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '28 Days', 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}}
Updated at
2024-02-23

1 organization

1 product

1 indication

Organization
Hopital of Melun
Product
Isoflurane
Indication
Refractory Status Epilepticus